fbpx

Meridian Enrolls First Participant in Moderna’s Phase 1 Epstein-Barr Virus Vaccine (mRNA-1189) Trial

Meridian Randomizes First Participant in Moderna’s Phase 1 Epstein-Barr Virus Vaccine Trial Brandon Essink, MD, CPI, is overseeing the Phase 1 Epstein-Barr virus vaccine (mRNA-1189) trial at Meridian’s dedicated research center in Omaha, NE

Meridian enrolled the first participant in Moderna’s Phase 1 clinical trial for an Epstein-Barr virus (EBV) vaccine candidate (mRNA-1189). Congratulations to Moderna, and to Brandon Essink, MD, CPI, and our team in Omaha, Nebraska!